Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking method to diabetes management. These innovative drugs work by mimicking the inherent actions of GLP-1, a hormone produced by the gut in response to meals. By activating GLP-1 receptors in the pancreas, these substances enhance insulin secretion and suppress glucagon out

The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting substantial weight decrease – they exhibit intriguing differences in t